What is sweet’s syndrome mouth sores pictures

That said, Sweet’s syndrome is thought to potentially involve other tissues and organs, in addition to the skin. Involvement of the bones and joints has been documented, as has involvement of the central nervous system—a “neuro-Sweet disease” has been described. The eyes, ears, and mouth can also be affected. Tender red bumps can extend from the external ear, into the canal and eardrum. The eyes can be involved, with swelling, redness, and inflammation. Sores on the tongue, inside the cheeks and on the gums may develop. Inflammation and/or enlargement of internal organs of the abdomen and chest has also been reported. Risk Factors

Sweet’s syndrome is very rare, so its risk factors are not as well developed as they might be for some other illnesses. In general, women are more likely to have Sweet’s syndrome than are men, and, although older adults and even infants can develop Sweet’s syndrome, people between the ages of 30 and 60 are the main affected age group.

Additionally, the conditions that define the types listed above may be considered risk factors, so Sweet’s syndrome is sometimes associated with cancer, it may be associated with sensitivity to certain drugs, it may follow an upper respiratory infection (and many people report having flu-like symptoms before the rash appears) and it can also be associated with inflammatory bowel disease, which includes Crohn’s disease and ulcerative colitis.

Skin biopsy, or removal of a small piece of the affected skin for examination under a microscope, may be performed. Sweet’s syndrome has characteristic abnormalities: inflammatory cells, mostly mature white blood cells of the neutrophil type, infiltrate and are typically located in an upper layer of the living part of the skin.

The most consistent laboratory findings in patients with Sweet’s syndrome are elevated white blood cells and neutrophils in the bloodstream and an elevated erythrocyte sedimentation rate, or ESR. That said, an elevated white blood cell count is not always seen in all patients with biopsy-confirmed Sweet’s syndrome. Treatment

Sweet’s syndrome may go away on its own, without any treatment, however treatments are effective and generally work quickly. Untreated, the rash can last for weeks to months. The most common medications used for Sweet’s syndrome are corticosteroids. Oral corticosteroids, such as prednisone, may be used, especially if you have more than a few areas of skin affected. These medications are systemic, meaning they go throughout the whole body and not just the skin.

Other forms of steroids such as creams or ointments are sometimes used for smaller, less widespread rashes. When a person with Sweet’s syndrome doesn’t tolerate systemic corticosteroids or has side effects with long-term corticosteroids, there are other medications that might be used, such as dapsone, potassium iodide, or colchicine.

Patients with Sweet’s syndrome may develop complications due to the skin involvement, the Sweet’s syndrome-associated conditions, or both. Antimicrobial therapy may be used if the skin sores from the rash are at risk for becoming secondarily infected.

Attention to any Sweet’s syndrome-associated conditions may also be an important part of the treatment of Sweet’s syndrome, itself. For instance, the symptoms associated with the syndrome sometimes remit with treatment or cure of the underlying malignancy. A Word From Verywell

Medications such as corticosteroids may provide relief from the syndrome, but attention to the underlying associated conditions may also be important. If you have the drug-induced type of Sweet’s syndrome, once the causative drug has been discontinued, the disease typically, but not always, improves and spontaneously remits.

Clearly, not everyone with Sweet’s syndrome has cancer; and, in a study with 448 people with Sweet’s syndrome, only 21 percent (or 96 of 448 individuals) were found to have either a hematologic malignancy or a solid tumor. Of note, however, is that Sweet’s syndrome can sometimes lead to the discovery of an unknown cancer—and also that the recurrence of malignancy-associated Sweet’s syndrome can signal a relapse of the cancer.

Hussein K, Nanda A, Al-Sabah H, Alsaleh QA. Sweet’s syndrome (acute febrile neutrophilic dermatosis) associated with adenocarcinoma of prostate and transitional cell carcinoma of urinary bladder. J Eur Acad Dermatol Venereol. 2005;19:597–599.